The plasma [Kyn]/[Trp] ratio, a measure of TDO or IDO activity, was reported [130] for nine AIP patients undergoing givosiran therapy over a 6–16-month period, and found to be unaltered. The gene discussed is TDO2; the disease is autoimmune pancreatitis.